Market Research Logo

Global Antibacterial Drugs Market 2019-2029

Global Antibacterial Drugs Market 2019-2029

The global antibacterial drugs market is estimated to have reach $43bn in 2018 and is expected to grow at a CAGR of 2% in the first half of the forecast period. The Cephalosporins submarket held 28% of the global antibacterial drugs market in 2018.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 297-page report you will receive 144 tables and 105 figures– all unavailable elsewhere.

The 297-page report provides clear detailed insight into the global antibacterial drugs market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

  • Global Antibacterial Drugs Market forecasts from 2019-2029
  • Revenue forecasts for the 6 leading submarkets from 2019-2029:
  • Cephalosporins
  • Penicillins
  • Fluoroquinolones
  • Macrolides
  • Carbapenems
  • Others
  • Revenue forecasts for the 43 leading marketed antibacterial drugs from 2019-2029:
  • Cephalosporins: Rocephin, Sulperazon, Ceftin/Zinnat, Meiact, Flomox, Teflaro, Zeftera, Ceftolozane-tazobactam, Ceftazidime-Avibactam
  • Penicillins: Generic amoxicillin, Augmentin, Zosyn/Tazocin, Unasyn, Generic amoxicllin-clavulanic acid, Amoxil
  • Fluoroquinolones: Avelox, Cravit, Vigamox, Ciprodex, Cipro/Ciprobay, Geninax, Defafloxacin
  • Macrolides: Biaxin/Clarith, Zithromax, Dalacin, Dificid, Solithromycin
  • Carbapenems: Invanz, Merrem/Meropen, Primaxin, Doribax
  • Other antibacterial drugs: Zyvox, Cubicin, Tygacil, TOBI/TIP, Solodyn, Vibativ, Sirturo, Tedizolid, Oritavancin, Dalbavancin, Nemonoxacin, Surotomycin
  • Revenue forecasts for the leading regional markets forecasted in this report are the following:
  • North America
  • Europe
  • Asia-Pacific
  • RoW
Each regional market is further segmented by the 6 leading submarkets.
  • Revenue forecasts for the leading national markets forecasted in this report are the following:
  • The US
  • Japan
  • Italy
  • France
  • The UK
  • Spain
  • Germany
  • China
  • India
  • Brazil
  • Russia
  • South Korea
  • This report discusses the selected leading companies:
  • Adenium Biotech ApS,
  • Allecra Therapeutics GmbH
  • AstraZeneca
  • Bayer
  • BioVersys AG
  • Eli Lilly
  • GlaxoSmithKline (GSK)
  • Merck & Co.
  • Novartis
  • Pfizer
  • Analysis of the strengths, weaknesses as well as the opportunities and threats of the antibacterial drugs industry and market
  • Coverage of antibacterial drug candidates in the R&D pipeline. Discussions of research and development – see progress in this industry, finding technological, clinical and commercial outlooks and opportunities
  • Key Questions Answered by this Report:
  • Gain forecasts from 2019 to 2029 for the overall world market and its leading submarkets, as well as those for prominent national markets.
  • Explore the regulatory landscape for leading regional and national markets, as well as expected developments for the period 2019-2029.
  • Identify drug development trends that will affect market participants from 2019 to 2029. This report contains SWOT and STEP analysis for the forecast period.
  • See discussions of companies developing, manufacturing and marketing antibiotics, exploring products, technologies, R&D, partnerships, M&A and outlooks.
Please Note: Prior to initiating fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.

The publisher is using a password system to access all reports. Single user (non-printable) and departmental licenses expires after 12 month period. In the case of departmental site license purchases, the publisher requires all email addresses for the licensed users prior to fulfillment.


1. Report Overview
1.1 Overview of Findings
1.2 Why You Should Read This Report
1.3 How This Report Delivers
1.4 Main Questions Answered by This Analysis
1.5 Who is This Study For?
1.6 Research and Analysis Methods
1.7 Frequently Asked Questions (FAQs)
1.8 Some Associated Reports
1.9 About Visiongain
2. Introduction to Antibacterial Drugs
2.1 Types of Bacterial Infection
2.2 Main Bacteria Causing Infections in Human Beings
2.3 Incidence and Mortality Profiles for Common Bacterial Infection
2.4 Treating Infections
2.4.1 The History of Antibacterial Drug Development
2.4.2 Mechanisms of Action
2.4.3 Leading Classes of Antibacterial Medicines
2.4.3.1 Cephalosporins
2.4.3.2 Penicillins
2.4.3.3 Carbapenems
2.4.3.4 Fluoroquinolones
2.4.3.5 Macrolides
2.4.4 Antibacterial Drug Resistance
3. Antibacterial Drugs: World Market 2019-2029
3.1 Antibacterial Drugs Revenues Plateau between 2013 and 2018
3.2 Antibacterial Agents - Market Segmentation
3.3 Antibacterial Drugs Market Forecast 2019-2029: Decline in Revenues for Fluoroquinolones
3.4 Drivers and Restraints in the Antibacterial Drugs Market, 2019-2029
3.5 Generic Erosion and Prescription Control Will Limit Market Growth
3.6 Changes in that Industry Sector’s Market Shares, 2019-2029
3.7 Pfizer is the Leader in the Antibacterial Drugs Market, 2018
3.8 Fragmented Market to Fracture Further
4. Cephalosporins Market Forecast 2019-2029
4.1 Cephalosporins Market 2018 – No Dominant Brands
4.1.1 Late-Stage Cephalosporins to Gain Market Share Between 2019 and 2029
4.1.2 Basilea, Merck, Actavis and AstraZeneca to Lead the Cephalosporins Market Between 2019 and 2029
4.1.3 Drivers and Restraints on the Cephalosporins Market, 2019-2029
4.1.4 Cephalosporins Lack Market Exclusivity
4.1.5 Strong Pipeline for Novel Cephalosporins
4.1.6 Rocephin (Roche) – The Only Treatment for Gonorrhoea in the US
4.1.6.1 Off Patent but Still Effective
4.1.6.2 Declining Revenues Owing to Competition - Forecast 2019-2029
4.1.7 Sulperazon – India’s Leading Treatment for RTIs and UTIs
4.1.7.1 Continued Growth in the Emerging Markets, Revenue Forecast 2019-2029
4.1.8 Zinnat/Ceftin – GSK’s Established Cephalosporin
4.1.8.1 Continued Decline in Revenue - Forecast 2019-2029
4.1.9 Meiact – A Broad Range Community Antibiotic
4.1.9.1 Spectracef Sales in the US Leads to Pass the Product
4.1.9.2 Competition in Japan to Hinder Growth – Revenue Forecast 2019-2029
4.1.10 Flomox - Shionogi’s Third-Generation Cephalosporin
4.1.10.1 Patent Issues and Litigation
4.1.10.2 Genericization and Safety to Restrict Sales - Forecast 2019-2029
4.1.11 Zinforo/Teflaro (ceftaroline fosamil): The First of the Fifth- Generation Cephalosporins
4.1.11.1 Unmet Needs in Pneumonia to Drive Growth - Revenue Forecast 2019-2029
4.1.12 Zeftera (ceftobiprole): Approved for Pneumonia in Europe
4.1.12.1 Future Sales Dictated by US Approval - Revenue Forecast 2019-2029
4.1.13 CXA-201 (Ceftolozane-Tazobactam): The Next Blockbuster Antibacterial
4.1.13.1 Broad Label and Spectrum of Activity Leads to Rapid Uptake - Revenue Forecast 2019-2029
4.1.14 Zavicefta (CAZ-AVI) (Ceftazidime-Avibactam): Approved in 2015
4.1.14.1 Competition from Zebraxa will Limit Sales of Zavicefta - Forecast 2019-2029
5. Penicillins Market Forecast 2019-2029
5.1 Generics and Augmentin Dominate the Penicillins Market in 2018
5.2 Augmentin to Lose its Dominance over the Coming 10 Years - Market Shares for Penicillin Drugs, 2019-2029
5.3 Penicillin Antibacterial Drugs: Market Forecast 2019-2029
5.4 Drivers and Restraints for the Penicillin Market 2019-2029
5.5 Augmentin – Blockbuster Facing Generic Competition
5.5.1 Augmentin – Challenges in Some Countries
5.5.2 Stable Revenues Regardless of Generic Competition
5.5.3 Revenue Forecast 2019-2029
5.6 Zosyn/Tazocin (Piperacillin-Tazobactam) - Pneumonia Therapeutic
5.6.1 Patent Expiry and Revenue Extension for Pfizer
5.6.2 Historic and Current Revenue Performance
5.6.3 Revenue Forecast 2019-2029
5.7 Unasyn – Gram-negative and Positive Antibiotic
5.7.1 Falling Revenues - Forecast 2019-2029
5.8 Amoxil (Amoxicillin) – A Historic Antibacterial Brand
5.8.1 Marginal Decline in Revenue - Forecast 2019-2029
5.9 Generic Amoxicillin
5.9.1 Revenue Forecast 2019-2029
5.10 Generic Amoxicillin-Clavulanic Acid
5.10.1 Revenue Forecast 2019-2029
6. Fluoroquinolones Market Forecast 2019-2029
6.1 The Fluoroquinolone Market 2018
6.2 Changing Market Share for Fluoroquinolone Antibacterial Drugs, 2019-2029
6.3 Fluoroquinolone Antibacterial Drugs: Market Forecast 2019-2029
6.4 Trends in the Fluoroquinolone Market
6.4.1 Safety Fears for Fluoroquinolones
6.4.2 Avelox Patent Cliff
6.4.3 Inhaled Fluoroquinolone Formulations
6.5 Fluoroquinolone Market Forecast 2019-2029
6.6 Avelox
6.6.1 Safety Profile Hampers Sales
6.6.2 Generic Competition
6.6.3 Revenue Forecast 2019-2029
6.7 Cravit/Levaquin (levofloxacin)
6.7.1 Generic Competition Affecting Revenue Worldwide
6.7.2 Lifecycle Management for Cravit and Levaquin
6.7.3 Revenue Forecast 2019-2029
6.8 Vigamox
6.8.1 Vigamox: Branded and Generic Challenges
6.8.2 Moxeza: A Next-Generation Form of Vigamox
6.8.3 Revenue Forecast 2019-2029
6.9 Ciprodex and Cipro – two Preparations of ciprofloxacin
6.9.1 Ciprodex: A Second-Generation Ophthalmic Antibiotic
6.9.1.1 Revenue Forecast 2019-2029
6.9.2 Cirpo Revenue Forecast 2019-2029: Continued Generic Erosion
6.10 Geninax
6.10.1 Revenue Forecast 2019-2029
6.11 Baxdela (delafloxacin)
6.11.1 Revenue Forecast 2019-2029
7. Macrolides Market Forecast 2019-2029
7.1 Macrolide Market in 2018
7.2 Changing Market Share for Macrolides, 2019-2029
7.3 Macrolide Antibacterial Drugs: Market Forecast 2019-2029
7.4 Trends in the Macrolide Market
7.5 Biaxin/Clarith
7.5.1 Past Revenue 2011-2015
7.5.2 Lifecycle Management for Continued Market Presence
7.5.3 Revenue Forecast 2019-2029
7.6 Zithromax
7.6.1 Concerns over Safety and Marketing in the US
7.6.2 Effectiveness in Drug-Resistant Strains
7.6.3 Revenue Forecast 2019-2029
7.7 Dalacin
7.7.1 Revenue Forecast 2019-2029
7.8 Dificid
7.8.1 Rapid Uptake Slowed by High Cost
7.8.2 New Approvals and Expanded Indications
7.8.3 Revenue Forecast 2019-2029
7.9 Solithera (solithromycin)
7.9.1 Revenue Forecast 2019-2029
8. Carbapenems Market Forecast 2019-2029
8.1 Carbapenem Market 2018
8.2 Changing Market Share for Carbapenems, 2019-2029
8.3 Carbapenem Antibacterial Drugs: Market Forecast 2019-2029
8.4 Trends in the Carbapenem Market
8.4.1 Rising Prevalence of Carbapenemases and β-Lactamases
8.4.2 No New Carbapenems in Late-Stage Trials
8.5 Merrem/Meropenem
8.5.1 Generics Affecting Revenue Worldwide
8.5.2 Revenue Forecast 2019-2029
8.6 Primaxin
8.6.1 Combination Therapy for Lifecycle Management
8.6.2 Historic and Current Revenues
8.6.3 Revenue Forecast 2019-2029
8.7 Invanz
8.7.1 Revenue Forecast 2019-2029
8.8 Doribax
8.8.1 Doribax in HAP and VAP
8.8.2 Lifecycle Management in Japan and the Rest of the World
8.8.3 Revenue Forecast 2019-2029
9. Other Antibacterial Drugs Forecast, 2019-2029
9.1 The Market for Other Classes of Antibacterial Drugs
9.2 Changing Market Share for Fluoroquinolone Antibacterials 2019-2029
9.3 Other Antibacterials: Market Forecast 2019-2029
9.4 Trends in the Other Classes of Antibacterial Drugs
9.4.1 New Oxazolidinones Will Drive Growth
9.4.2 New Drug Classes to Drive Submarket Growth to 2029
9.5 Zyvox – The Market Leading Antibacterial
9.5.1 MRSA Activity Driving Revenue Growth
9.5.2 Promise in Tuberculosis and Anthrax
9.5.3 Patents, Litigation, and Competition – When and Who Will Produce Generic Linezolid?
9.5.4 Flat Growth to Patent Expiry, Revenue Forecast 2019-2029
9.6 Cubicin – The Leading Brand for ABSSSIs
9.6.1 Revenue Boosted by Approvals Worldwide
9.6.2 Patents, Litigation and Deals – How Long Will Market Exclusivity Last?
9.6.3 Sustained Growth through to 2021, Revenue Forecast 2019-2029
9.7 Tygacil – A Tetracycline with Many Approved Indications
9.7.1 Concerns Limiting Revenue Potential
9.7.2 Competition from Other Therapies Restricts Growth: Revenue Forecast 2019-2029
9.8 TOBI/TOBI Podhaler – The Market Leading Inhaler for Cystic Fibrosis
9.8.1 Historic and Current Revenue Performance
9.8.2 Approvals and Launches in New Markets to Drive Revenue Growth
9.8.3 Competition to Limit Long-term Growth, Revenue Forecast 2019-2029
9.9 Solodyn – A Treatment for Severe Acne
9.9.1 Generic Competition and Lifecycle Management
9.9.2 Limited Potential for Dermatology, Revenue Forecast 2019-2029
9.10 Vibativ – Limited Potential for Novel Lipoglycopeptide
9.10.1 Astellas Ends its Collaboration with Theravance
9.10.2 Limited HAP Label in the US - Revenue Forecast 2019-2029
9.11 Sirturo – A New Option for Multi-Drug Resistant TB
9.11.1 Chronic Treatment Schedule and Emerging Demand Drive Revenue Growth, Forecast 2019-2029
9.12 Tedizolid – Market Leading Follow-on to Zyvox?
9.12.1 Competition Increasing: Revenue Forecast 2019-2029
9.13 Oritavancin – An Antibiotic with a Novel PK Profile
9.13.1 Single Dose Differentiation to Deliver Market Share (%), Revenue Forecast 2019-2029
9.14 Dalvance (dalbavancin) – Competing in a Crowded Indication
9.14.1 Sustained Growth Over the Coming 10 Years, Revenue Forecast 2019-2029
9.15 Surotomycin –Treatment for C. difficile
9.15.1 Delayed Launch to Limit Potential, Revenue Forecast 2019-2029
9.16 Nemonoxacin – Taiwan’s Global Antibacterial Drug
9.16.1 Slow Initial Growth to Accelerate with US Approval, Revenue Forecast 2019-2029
10. Global Anti-Bacterial Drugs Market by Region 2019-2029
10.1 North America Antibacterial Drugs Market, by Sector 2019-2029
10.2 Europe Antibacterial Drugs Market, by Sector 2019-2029
10.3 Asia-Pacific Antibacterial Drugs Market, by Sector 2019-2029
10.4 Rest-of-the-World Antibacterial Drugs Market, by Sector 2019-2029
11. The Leading National Markets 2019-2029
11.1 US and China Dominate the Global Antibacterial Market
11.2 Above-Average Growth in US: Regional Forecasts 2019-2029
11.3 China to Slump in Market Share, While Brazil and India Push on
11.4 Incidence of Infection by Country, 2016
11.4.1 Incidence of Pneumonia in National Markets – Pneumonia Predominant in America
11.4.2 Incidence of Community Acquired Urinary Tract Infections in National Markets – High Incidence Rates in the UK, US and Spain
11.4.3 Incidence of Bacterial Skin and Skin Structure Infections in National Markets – High Potential in the US
11.4.4 Incidence of Upper Respiratory Tract Infections in National Markets – Europe Leads the Way
11.5 Antibacterial Drug Consumption by Country, 2016
11.5.1 Antibacterial Drug Consumption in the Major National Markets
11.5.2 Antibacterial Drug Consumption in Some Other National Markets
11.6 The Antibacterials Market in the US
11.6.1 Continued Dominance of the US Market
11.7 The European Union Forms Second Largest Regional Market
11.7.1 Marginal Expansion in Antibacterial Spending – Market Forecast 2019-2029
11.7.2 Action to Encourage Antibacterial Drug Development in the EU
11.7.3 Italy Continues to Lead the Way in Antibiotic Use
11.7.4 The French Fascination with Expensive Antibacterial Drugs
11.7.5 Germany – Europe’s Antibiotic Steward
11.7.6 Rising Use of Antibacterials Drugs in the UK
11.7.7 Spanish Antibacterials Market to Expand from 2021 to 2027
11.8 Japan – Still the Fourth Largest National Market
11.8.1 The Pause before Growth in the Japanese Market
11.9 Will South Korea Continue Its High Use of Antibiotics?
11.10 BRIC Nation Sales Still Expanding – Market Forecast 2019-2029
11.11 Chinese Antibacterial Market Bloated by Reported Overuse
11.11.1 Developing Antibacterials in China, for China
11.11.2 Governmental Controls Subdue Recent Growth – Market Forecast 2019-2029
11.12 Indian Market to Expand by 50% Over the Forecast Period
11.12.1 Restricting Antibiotic Use in India
11.12.2 Sustained Expansion of the Indian Market, Forecast 2019-2029
11.13 Brazilian Antibacterial Market to Double in Size
11.13.1 Brazilian Market to Be Driven by Drug Resistance
11.14 Russia: TB Prevalence to Stimulate Antibiotic Sales - Forecast 2019-2029
12. Leading Companies in the Antibacterial Drugs Market
12.1 Pfizer Inc.
12.1.1 Overview
12.1.2 Financials
12.1.3 Pipeline Portfolio
12.1.4 Key Developments
12.2 Novartis AG
12.2.1 Overview
12.2.2 Financials
12.2.3 Pipeline Portfolio
12.2.4 Key Developments
12.3 Merck & Co. Inc.
12.3.1 Overview
12.3.2 Financials
12.3.3 Product Portfolio
12.3.4 Key Developments
12.4 GlaxoSmithKline PLC
12.4.1 Overview
12.4.2 Financials
12.4.3 Product Portfolio
12.4.4 Key Developments
12.5 BioVersys AG
12.5.1 Overview
12.5.2 Pipeline Portfolio
12.5.3 Key Developments
12.6 AstraZeneca PLC
12.6.1 Overview
12.6.2 Financials
12.6.3 Pipeline Portfolio
12.6.4 Key Developments
12.7 Allecra Therapeutics GmbH
12.7.1 Overview
12.7.2 Pipeline Portfolio
12.7.3 Key Developments
12.8 Adenium Biotech ApS
12.8.1 Overview
12.8.2 Pipeline Portfolio
12.9 Bayer AG
12.9.1 Overview
12.9.2 Financials
12.9.3 Product Portfolio
12.10 Eli Lilly and Company
12.10.1 Overview
12.10.2 Financials
12.10.3 Pipeline Portfolio
13. Antibacterials R&D Pipeline Review, 2018
13.1 Gram-Positive vs. Gram-Negative
13.2 Pipeline Dominated by Small Molecule Drugs
13.3 Some of the Leading Phase I Drug Candidates
13.3.1 Nemiralisib (GlaxoSmithKline plc)
13.3.2 Piperacillin/AAI101 (Allecra Therapeutics GmbH
13.3.3 MEDI3502 (AstraZeneca plc)
13.3.4 PF-06760805 (Pfizer, Inc.)
13.3.5 GSK3335065 (GlaxoSmithKline plc)
13.4 Some of Leading Phase II Drug Candidates
13.4.1 Cefepime/AAI101 (Allecra Therapeutics GmbH)
13.4.2 Gepotidacin (GlaxoSmithKline plc)
13.4.3 GSK3536852A (GlaxoSmithKline plc)
13.4.4 QBW251 (Novartis AG)
13.4.5 GSK2982772 (GlaxoSmithKline plc)
13.5. Some of the Leading Phase III Drug Candidates
13.5.1 V114 (Merck & Co., Inc.)
13.5.2 ZERBAXA (Merck & Co., Inc.)
13.5.3 PT010 (AstraZeneca plc)
14. Qualitative Analysis of the Antibacterial Industry and Market, 2019-2029
14.1 SWOT Analysis: Strengths, Weaknesses, Opportunities and Threats Affecting Antibacterials, their Developers, Producers and Marketers
14.2 STEP Analysis: Social, Technological, Economic and Political Forces Affecting the Antibacterial Drug Industry and Market
14.2.1 Social Factors
14.2.2 Technological Developments
14.2.3 Economic Pressures
14.2.4 Political Issues
14.3 Market is Well Established and Demand Will Remain Strong
14.4 High Prevalence of Bacterial Infection Worldwide
14.5 Worldwide Demand for Antibacterials
14.6 Animal Models of Infection are Highly Predictive Compared with Other Therapeutic Fields
14.7 Cutting into a Saturated Market
14.8 Superior Benefit over Generics?
14.9 Resistance – Nature’s Patent Expiry
14.10 Acute Treatment Limits Commercial Potential
14.11 Did Big Pharma Back Away from Antibacterial Drugs?
14.12 Resistance Will Continue to Present New Targets
14.13 First Biologic Antibacterials
14.14 Potential for Smaller Firms to Capitalise
14.15 Developing Preventative Vaccines Rather Than Treatments
14.16 Antibacterial Stewardship Reduces Usage
14.17 Clinical Confusion from Inconsistent Guidance Between Regulatory Bodies
14.17.1 Therapeutic Success in European Clinical Trials
14.17.2 Primary End Points in FDA Guidelines
14.18 Reduction in Hospital Infection Rates - Reducing Demand for Antibacterial Drugs
14.19 Enticing Antibacterial Drug Discovery – Push and Pull Incentives
14.19.1 GAIN act: Post-Development Pull Incentives in the US
14.19.2 ADAPT – Building on the GAIN act
14.19.3 EMA Update Guideline – Streamlining Clinical Trials in the EU
14.19.4 Push Incentives for Antibacterial Drug Discovery with Public Funding
14.19.5 IMI: Public-Private Collaboration with GSK and AstraZeneca
14.19.6 Public Finance Pumping Money into Antibacterial Development
15. Antibacterial Drugs Market 2019 - 2029: Conclusions
15.1 Three Blockbuster Antibacterials in 2018 - Leading Brands
15.2 The Leading Branded Antibacterial Drugs in 2029
15.3 Stemming the Tide of Antibacterial Drug Resistance
15.4 The Changing Face of Antibacterial Clinical Development
Appendices
Some Associated Visiongain Reports
Visiongain Report Sales Order Form
About Visiongain
Visiongain Report Evaluation Form
List of Tables
Table 2.1 Common Bacterial Infections and Their Causes
Table 2.2 Details of the ESKAPE Bacteria
Table 2.3 Leading Causes of Infectious Diseases Deaths Worldwide, 2010
Table 2.4 Mechanisms of Action for Antibacterial Drugs
Table 3.1 Antibacterial Drugs: Historic Global Market Size ($bn), Annual Growth (%), and CAGR (%), 2013-2018
Table 3.2 Global Antibacterial Drug Market by Sector: Market Size ($bn) and Share (%), 2018
Table 3.3 Global Antibacterial Drugs Market: Revenue Forecasts by Sector ($bn), Annual Growth (%) and CAGR, 2019-2029
Table 3.4 Antibacterial Drugs Market: Forecasted Sector Market Shares (%), 2018-2029
Table 3.5 Leading Branded Antibacterials Manufacturers: Revenues ($bn) and Market Shares (%), 2018
Table 4.1 Leading Branded Cephalosporin Antibacterial Drugs: Important Facts, 2018
Table 4.2 Cephalosporin Market by Product: Revenue ($bn) and Market Share (%), 2018
Table 4.3 Cephalosporin Market by Product: Revenue ($bn) and Market Share (%), 2021
Table 4.4 Cephalosporin Market by Product: Revenue ($bn) and Market Share (%), 2029
Table 4.5 Cephalosporin Market Forecast by Product: Revenue ($bn), Annual Growth (%), CAGR (%), 2019-2029
Table 4.6 Cephalosporin Market Forecast by Product: Market Share (%), 2018-2029
Table 4.7 Rocephin Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2019-2029
Table 4.8 Sulperazon Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2019-2029
Table 4.9 Zinnat/Ceftin Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2019-2029
Table 4.10 Meiact Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2019-2029
Table 4.11 Flomox Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2019-2029
Table 4.12 Zinforo in-vitro Antibacterial Activity: Gram-positive and Gram-negative Bacteria
Table 4.13 Zinforo/Teflaro Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2019-2029
Table 4.14 Zeftera Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2019-2029
Table 4.15 Zerbraxa Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2019-2029
Table 4.16 Zavicefta Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2019-2029
Table 5.1 Leading Branded Penicillin Drugs: Important Facts
Table 5.2 Penicillin Market by Product: Revenue ($bn) and Market Shares (%), 2018
Table 5.3 Penicillin Market by Product: Revenue ($bn) and Market Shares (%), 2019
Table 5.4 Penicillin Market by Product: Revenue ($bn) and Market Shares (%), 2029
Table 5.5 Penicillin Market Forecast by Product: Revenue ($bn), Annual Growth (%), CAGR (%), 2019-2029
Table 5.6 Penicillin Market Forecast by Product: Market Share (%), 2019-2029
Table 5.7 Augmentin Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2019-2029
Table 5.8 Zosyn/Tazocin Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2019-2029
Table 5.9 Unasyn Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2019-2029
Table 5.10 Amoxil Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2019-2029
Table 5.11 Generic Amoxicillin Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2019-2029
Table 5.12 Generic Amoxicillin-Clavulanic Acid Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2019-2029
Table 6.1 Leading Branded Fluoroquinolone Drugs: Important Facts
Table 6.2 Fluoroquinolone Market by Product: Revenue ($bn) and Market Share (%), 2018
Table 6.3 Fluoroquinolone Market by Product: Revenue ($bn) and Market Share (%), 2019
Table 6.4 Fluoroquinolone Market by Product: Revenue ($bn) and Market Share (%), 2029
Table 6.5 Fluoroquinolone Market Forecast by Product: Revenue ($bn), Annual Growth (%), CAGR (%), 2019-2029
Table 6.6 Fluoroquinolone Market Forecast by Product: Market Share (%), 2018-2029
Table 6.7 Avelox Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2019-2029
Table 6.8 Generic Manufacturers of Levofloxacin, 2017
Table 6.9 Cravit/Levaquin Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2019-2029
Table 6.10 Vigamox Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2019-2029
Table 6.11 Ciprodex Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2019-2029
Table 6.12 Cipro/Ciprobay Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2019-2029
Table 6.13 Geninax Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2019-2029
Table 6.14 Baxdxela Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2019-2029
Table 7.1 Leading Branded Macrolides: Important Facts
Table 7.2 Macrolide Market by Product: Revenue ($bn) and Market Share (%), 2018
Table 7.3 Macrolide Market by Product: Revenue ($bn) and Market Share (%), 2019
Table 7.4 Macrolide Market by Product: Revenue ($bn) and Market Share (%), 2029
Table 7.5 Macrolide Market Forecast by Product: Revenues ($bn), Annual Growth (%), CAGR (%), 2019-2029
Table 7.6 Macrolide Market Forecast by Product: Market Shares (%), 2019-2029
Table 7.7 Biaxin/Clarith Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2019-2029
Table 7.8 Zithromax Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2019-2029
Table 7.9 Dalacin Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2019-2029
Table 7.10 Dificid Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2019-2029
Table 7.11 Solithera Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2019-2029
Table 8.1 Leading Branded Carbapenems: Important Facts
Table 8.2 Carbapenem Market by Product: Revenue ($bn) and Market Share (%), 2018
Table 8.3 Carbapenem Market by Product: Revenue ($bn) and Market Share (%), 2019
Table 8.4 Carbapenem Market by Product: Revenue ($bn) and Market Share (%), 2029
Table 8.5 Carbapenem Market Forecasts by Product: Revenues ($bn), Annual Growth (%), CAGR (%), 2019-2029
Table 8.6 Carbapenem Market Forecast by Product: Market Share (%), 2019-2029
Table 8.7 Merrem Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2019-2029
Table 8.8 Primaxin Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2019-2029
Table 8.9 Invanz Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2019-2029
Table 8.10 Doribax Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2019-2029
Table 9.1 Other Leading Branded Antibacterials: Important Facts
Table 9.2 Other Classes of Antibacterial Drugs by Product: Revenue ($bn) and Market Share (%), 2018
Table 9.3 Other Classes of Antibacterial Drugs by Product: Revenue ($bn) and Market Share (%), 2019
Table 9.4 Other Classes of Antibacterial Drugs by Product: Revenue ($bn) and Market Share (%), 2029
Table 9.5 Others Market Forecasts by Product: Revenues ($bn), Annual Growth (%), CAGR (%), 2019-2029
Table 9.6 Other Agents: Market Forecast by Product - Market Share (%), 2018-2029
Table 9.7 Oxazolidinones in Mid to Late Stage Clinical Development, 2017
Table 9.8 Zyvox Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2019-2029
Table 9.9 Cubicin Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2019-2029
Table 9.10 Tygacil Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2019-2029
Table 9.11 TOBI/TOBI Podhaler Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2019-2029
Table 9.12 Solodyn Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2019-2029
Table 9.13 Vibativ Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2019-2029
Table 9.14 Sirturo Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2019-2029
Table 9.15 Tedizolid Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2019-2029
Table 9.16 Oritavancin Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2019-2029
Table 9.17 Dalvance Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2019-2029
Table 9.18 Surotomycin Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2019-2029
Table 9.19 Nemonoxacin Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2019-2029
Table 10.1 Antibacterial Drug Sales by Regions: Market Size ($bn) and Share (%), 2018
Table 10.2 North America Antibacterial Drug Sales, 2018-2029
Table 10.3 Europe Antibacterial Drug Sales, 2018-2029
Table 10.4 Asia-Pacific Antibacterial Drug Sales, 2018-2029
Table 10.5 Rest-of-the-World Antibacterial Drug Sales, 2018-2029
Table 11.1 Antibacterial Drug Sales by National and Regional Markets: Market Size ($bn) and Share (%), 2018
Table 11.2 Antibacterial Drug Markets: National and Regional Market Sizes ($bn), Annual Growth (%), and CAGR (%), 2019-2029
Table 11.3 Antibacterial Drug Markets: National and Regional Market Shares (%), 2018-2029
Table 11.4 Incidence of Pneumonia in National Markets, 2016
Table 11.5 Incidence of Community Acquired Urinary Tract Infections in National Markets, 2016
Table 11.6 Incidence of Bacterial Skin and Skin Structure Infections in National Markets, 2016
Table 11.7 Incidence of Upper Respiratory Tract Infections in National Markets, 2016
Table 11.8 Antibacterial Drug Consumption in the Major National Markets: DDD per Capita per Day and Absolute DDD per year, 2016
Table 11.9 Antibacterial Drug Consumption in the Smaller National Markets: DDD per Capita per Day and Absolute DDD per year, 2016
Table 11.10 US Antibacterial Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2019-2029
Table 11.11 EU Antibacterial Drugs Market Overall and by Leading Country (EU5): Revenue Forecasts ($bn), Annual Growth (%), CAGR (%), 2019-2029
Table 11.12 Italian Antibacterial Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2019-2029
Table 11.13 French Antibacterial Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2019-2029
Table 11.14 German Antibacterial Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2019-2029
Table 11.15 UK Early Stage Antibacterial Drug Developers, 2016
Table 11.16 UK Antibacterial Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2019-2029
Table 11.17 Spanish Antibacterial Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2019-2029
Table 11.18 Japanese Antibacterial Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2019-2029
Table 11.19 South Korean Antibacterial Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2019-2029
Table 11.20 Antibacterial Drugs Market in BRIC Nations: National Revenue Forecasts ($bn), Annual Growth (%), CAGR (%), 2019-2029
Table 11.21 Chinese Antibacterial Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2019-2029
Table 11.22 Indian Antibacterial Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2019-2029
Table 11.23 Brazilian Antibacterial Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2019-2029
Table 11.24 Russian Antibacterial Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2019-2029
Table 12.1 Pfizer Inc. Recent Financials, 2015-2017
Table 12.2 Pfizer Inc. Recent Financials, 2015-2017
Table 12.3 Novartis AG: Pipeline Portfolio
Table 12.4 Novartis AG: Developments
Table 12.5 Merck & Co. Inc.: Product Portfolio
Table 12.6 Merck & Co. Inc.: Developments
Table 12.7 Merck & Co. Inc.: Product Portfolio
Table 12.8 GlaxoSmithKline PLC: Developments
Table 12.9 BioVersys AG: Pipeline Portfolio
Table 12.10 BioVersys AG: Pipeline Portfolio
Table 12.11 AstraZeneca PLC: Product Portfolio
Table 12.12 AstraZeneca PLC: Developments
Table 12.13 Allecra Therapeutics GmbH: Pipeline Portfolio
Table 12.14 Allecra Therapeutics GmbH: Developments
Table 12.15 Adenium Biotech ApS: Pipeline Portfolio
Table 12.16 Bayer AG Product Portfolio
Table 12.17 Eli Lilly and Company: Recent Financials, 2015-2017
Table 13.1 Antibacterial Drug Candidates in Phase I Development, 2018
Table 13.2 Antibacterial Drug Candidates in Other Drug Development Phase, 2018
Table 13.3 Antibacterial Drug Candidates in Phase II Development, 2018
Table 13.4 Antibacterial Drug Candidates in Phase III Development, 2018
Table 14.1 Social, Technological, Economic, and Political Factors Affecting the Antibacterial Drug Market, 2019-2029
Table 14.2 Bacterial Related Funding for BARDA, 2011-2014
Table 15.1 World Antibacterial Drugs Market by Class: Revenues ($bn), Market Shares (%), CAGRs (%), 2019, 2021, 2024, and 2029
List of Figures
Figure 2.1 Leading Causes of Infectious Disease Deaths Worldwide, 2010
Figure 2.2 Key Events in the History of Antibacterial Drug Development
Figure 3.1 Historic Global Market Size ($bn), 2013-2017
Figure 3.2 Global Antibacterial Drug Market by Sector: Market Share (%), 2018
Figure 3.3 Global Antibacterial Drugs Market: Forecasted Sector (Class) Revenues ($bn), 2019-2029
Figure 3.4 Antibacterial Drugs Market: Forecasted Sector Market Shares (%), 2019
Figure 3.5 Antibacterial Drugs Market: Forecasted Sector Market Shares (%), 2029
Figure 3.6 Leading Branded Antibacterial Manufacturers: Market Share (%), 2018

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report